Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 GeneticVariation group CLINVAR
Entrez Id: 708
Gene Symbol: C1QBP
C1QBP
0.010 AlteredExpression group BEFREE <b>Introduction:</b> Globular C1q receptor (gC1qR/p32/HABP1) is overexpressed in a variety of cancers, particularly adenocarcinomas. 31681580 2019
Entrez Id: 50506
Gene Symbol: DUOX2
DUOX2
0.010 Biomarker group BEFREE <b>Materials and Methods:</b> DUOX2 immunostain was performed in 172 rectal adenocarcinomas treated with preoperative CCRT followed by radical proctectomy, which were divided into high- and low-expression subgroups. 28928864 2017
Entrez Id: 4142
Gene Symbol: MAS1
MAS1
0.010 Biomarker group BEFREE <b>Methods</b>: In this study we analyzed the immunohistochemical expression of three main RAS receptors (AT1, AT2 and MAS) in a large series of CRC samples (n=161), including uninvolved intestinal mucosa-adenoma-adenocarcinoma sequences from the same patients (n=50). 31337954 2019
Entrez Id: 836
Gene Symbol: CASP3
CASP3
0.080 Biomarker group BEFREE <b>Methods</b>: In this study, we evaluated for the first time the prognostic value of Plk1 mRNA and protein expression in combination with the <i>TP53</i> mutation status (next generation sequencing), induction of apoptotic cell death (immunohistochemistry for cleaved caspase 3) and hypoxia (immunohistochemistry for carbonic anhydrase IX (CA IX)) in 98 NSCLC adenocarcinoma patients. 28638459 2017
Entrez Id: 768
Gene Symbol: CA9
CA9
0.060 Biomarker group BEFREE <b>Methods</b>: In this study, we evaluated for the first time the prognostic value of Plk1 mRNA and protein expression in combination with the <i>TP53</i> mutation status (next generation sequencing), induction of apoptotic cell death (immunohistochemistry for cleaved caspase 3) and hypoxia (immunohistochemistry for carbonic anhydrase IX (CA IX)) in 98 NSCLC adenocarcinoma patients. 28638459 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression group BEFREE <b>Methods:</b> Immunohistochemical expression of PD-L1 on tumour cells (TC) and tumour-infiltrating immune cells (TIC), and of PD-1 (programmed death receptor 1) on TIC was assessed using tissue microarrays with primary tumours and a subset of paired lymph node metastases from a consecutive, retrospective cohort of 174 patients with chemoradiotherapy-naïve EG adenocarcinoma. 30931254 2019
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.030 Biomarker group BEFREE <b>Purpose:</b> We investigated MYCN-regulated molecular pathways in castration-resistant prostate cancer (CRPC) classified by morphologic criteria as adenocarcinoma or neuroendocrine to extend the molecular phenotype, establish driver pathways, and identify novel approaches to combination therapy for neuroendocrine prostate cancer (NEPC).<b>Experimental Design and Results:</b> Using comparative bioinformatics analyses of CRPC-Adeno and CRPC-Neuro RNA sequence data from public data sets and a panel of 28 PDX models, we identified a MYCN-PARP-DNA damage response (DDR) pathway that is enriched in CRPC with neuroendocrine differentiation (NED) and CRPC-Neuro. 29138344 2018
Entrez Id: 100302276
Gene Symbol: MIR1290
MIR1290
0.010 Biomarker group BEFREE <b>Results</b>: After integrated analysis of GEO datasets, we discovered miR-1290 and miR-320d were dysregulated in colorectal adenoma and adenocarcinoma tissues, and circulating miR-1290 and miR-320d in CRC patients were tumor-derived. 30662524 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.400 AlteredExpression group BEFREE <b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). 31157548 2019
Entrez Id: 115482713
Gene Symbol: H3P10
H3P10
0.100 AlteredExpression group BEFREE <b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). 31157548 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.700 AlteredExpression group BEFREE <b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). 31157548 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.400 GeneticVariation group BEFREE <i>EGFR</i> mutation is highly related to female, nonsmoking and adenocarcinoma. 30210620 2018
Entrez Id: 238
Gene Symbol: ALK
ALK
0.100 GeneticVariation group BEFREE <i>ALK</i> positivity was significantly associated with younger age (P<0.001), solid predominant adenocarcinoma (P<0.001), variants of invasive adenocarcinoma (P<0.001), higher frequency of pleura invasion (P=0.040), smaller tumor size (P=0.014), mediastinal lymph node involvement (N2; P<0.001) and later pathologic stage (IIIA; P=0.001). 31737311 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression group BEFREE <i>EGFR</i> mutant adenocarcinomas with distinctive clinicopathologic features, especially solid histologic pattern and higher stage showed higher PD-L1 expression. 31561631 2019
Entrez Id: 23411
Gene Symbol: SIRT1
SIRT1
0.100 Biomarker group BEFREE <i>Methods:</i> Tumor weight, area, T cells and tumor growth (immunohistochemistry), oxidative stress, apoptosis, autophagy, and signaling (NF-κB and sirtuin-1) markers were analyzed (immunoblotting) in subcutaneous tumor of BALB/c mice injected with LP07 adenocarcinoma cells treated with monoclonal antibodies (CD-137, CTLA-4, PD-1, and CD-19, <i>N</i> = 9/group) and non-treated control animals. 31487876 2019
Entrez Id: 406959
Gene Symbol: MIR183
MIR183
0.020 AlteredExpression group BEFREE <i>Results.</i> Preoperative radiological findings, serum CEA level, serum microRNA-183 (miR-183) level, and tumour size differed significantly between patients with adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA) and those with invasive adenocarcinoma (IAC). 28115792 2016
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker group BEFREE (3) Also, the neu gene encoded protein p185 has been associated with a more aggressive clinical course in adenocarcinomas. 1962774 1990
Entrez Id: 4758
Gene Symbol: NEU1
NEU1
0.030 Biomarker group BEFREE (3) Also, the neu gene encoded protein p185 has been associated with a more aggressive clinical course in adenocarcinomas. 1962774 1990
Entrez Id: 9148
Gene Symbol: NEURL1
NEURL1
0.030 Biomarker group BEFREE (3) Also, the neu gene encoded protein p185 has been associated with a more aggressive clinical course in adenocarcinomas. 1962774 1990
Entrez Id: 8661
Gene Symbol: EIF3A
EIF3A
0.050 Biomarker group BEFREE (3) Also, the neu gene encoded protein p185 has been associated with a more aggressive clinical course in adenocarcinomas. 1962774 1990
Entrez Id: 10159
Gene Symbol: ATP6AP2
ATP6AP2
0.010 Biomarker group BEFREE (Pro)renin Receptor Expression Increases throughout the Colorectal Adenoma-Adenocarcinoma Sequence and It Is Associated with Worse Colorectal Cancer Prognosis. 31238566 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.400 GeneticVariation group BEFREE - Recurrent epidermal growth factor receptor ( EGFR) mutations are seen in a subset of pulmonary adenocarcinomas. 29106293 2018
Entrez Id: 5743
Gene Symbol: PTGS2
PTGS2
0.600 GeneticVariation group LHGDN -765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. 17006983 2006
Entrez Id: 1015
Gene Symbol: CDH17
CDH17
0.050 Biomarker group BEFREE -CDH17 immunostaining was positive in 97.3% (145 of 149) of colon adenocarcinomas, whereas CK20 and CDX2 stained positively in 88.6% (132 of 149) and 93.3% (139 of 149), respectively. 28029907 2017